Niagen Bioscience (NAGE) Insider Patrick Buys 31,746 Shares

Insider Buying and Selling at Niagen Bioscience, Inc.

Kristin Patrick acquired 31,746 shares of Niagen Bioscience, Inc. (NasdaqCM: NAGE) on June 24, 2026. This transaction formed part of a coordinated series of purchases by multiple company insiders on the exact same date, drawing attention to internal participation in the firm.

Multiple Insiders Expand Stakes

The transaction wasn't an isolated event for Niagen Bioscience. On June 24, 2026, several other key figures stepped in to pick up identical blocks of stock. Yu Wing Tak Wendy, Hamed Shahbazi, Steven Rubin, Ann Cohen, and Ng Wang Yu Gary each purchased 31,746 shares of Niagen Bioscience on that day. Together, these moves brought matching tranches of equity into the hands of multiple insiders simultaneously.

Stock Performance and Recent Levels

Shares of Niagen Bioscience recently changed hands around $3.42. The equity has traded within a 52-week range spanning from a low of $2.87 up to a high of $10.52. Market participants often monitor internal transactions to see how leaders interact with prevailing equity prices as shares fluctuate across the trading sessions.

Business Background

Niagen Bioscience, Inc. focuses on bioscience research and consumer health products. The company develops ingredients and finished dietary supplements centered on healthy aging and cellular metabolism, supplying raw materials and direct-to-consumer goods. Its product portfolio features proprietary ingredients distributed via online channels, specialized retail partners, and healthcare networks.

Future Watch Points

Observers tracking Niagen Bioscience can look toward future corporate updates and scheduled disclosures for further operational details. The company operates within the packaged foods and consumer defensive industry, maintaining a commercial footprint centered on its proprietary metabolic ingredients and dietary product lines.